Mohali plant supply suspension continues
Supplies from Mohali have not resumed; residual inventory sales are declining. Market share loss may be permanent depending on competition and contracts.
SUNPHARMA / bear-case history
Track the concerns that keep returning.
Sunpharma · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
India market share decline and NLEM impact
India market share fell to 8.33% from 8.5% due to NLEM price cuts and sitagliptin patent expiry. Recovery timeline uncertain.
Taro acquisition uncertainty
Management provided no update on the Taro minority buyout beyond forming a special committee. Strategic benefits remain unclear.
Specialty R&D pipeline execution risk
Multiple Phase II/III trials (ILUMYA PsA, deuruxo, GLP-1) require significant investment. Failure or delay could impact returns.
Leqselvi launch delay due to litigation
Incyte filed a preliminary injunction motion to block Leqselvi launch; outcome uncertain and could delay revenue contribution.
Halol plant re-audit timeline uncertain
Management plans to request FDA re-audit once ready, but no specific timeline provided; pending approvals may impact U.S. generic pipeline.
U.S. generic revenue flat despite Revlimid contribution
U.S. generic sales were flat sequentially; Revlimid contribution was not large this quarter, and sustainability is uncertain.
FDA warning letters at three facilities
Halol, Mohali, and Dadra facilities remain under FDA warning letters, limiting generic approvals and U.S. supply flexibility.
Lenalidomide pricing pressure
Generic lenalidomide continues to face pricing erosion, impacting U.S. generic business performance.
Leqselvi and UNLOXCYT launch execution risk
New product launches may face slower-than-expected formulary coverage or market adoption, impacting revenue ramp.
Potential U.S. tariffs on pharmaceuticals
While currently exempt, pharma may face tariffs after the 232 investigation, which could impact U.S. business margins.
Halol plant remediation uncertainty
Halol plant remains under FDA scrutiny; no timeline for re-inspection or resolution, impacting US generic supply.
Taro Israel operations exposure
Taro's operations in Israel may be impacted by regional conflict, though management says business continuity is maintained.
US generic pricing pressure
Management sees no significant improvement in generic pricing environment; pricing remains product-specific and competitive.
Leqselvi patent litigation binary outcome
The Leqselvi launch depends on a favorable court ruling on the '335 patent; an unfavorable outcome could delay launch until patent expiry in Dec 2026.
R&D spend may remain below guidance if trials delay further
Management acknowledged that further delays in clinical trials could keep R&D spend below the revised 7-8% guidance.
Higher selling expenses pressuring margins
Other expenses rose significantly due to higher selling and distribution costs in US and EM, which could pressure margins if not offset by revenue growth.
Japan price cuts impacting ROW revenues
Price cuts in Japan are expected to continue pressuring ROW revenues for the next few quarters, as mentioned by management.
US tariff uncertainty on innovative medicines
Potential tariffs on patented drug imports into the US could impact Sun Pharma's innovative portfolio, though generics are expected to be excluded.
Lenalidomide revenue decline
Lenalidomide sales have dropped YoY and are expected to be minimal in the second half, impacting US generics revenue.
Higher effective tax rate normalization
ETR increased to 24.7% from 15.8% YoY due to expiry of tax benefits, expected to hover around 25%, pressuring net profit growth.
Competition in alopecia areata market
Stagnation in prescriptions for existing targeted treatments could hinder Leqselvi's uptake, though management expects market growth.
Mohali plant supply constraints persist
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
CEQUA facing increased competition in dry eye space
CEQUA's market share has declined due to generic Restasis and new entrants with different mechanisms of action.
Red Sea supply chain disruption risk
Management is monitoring the Red Sea situation; potential for shipment delays if situation does not normalize.
Taro merger may not receive minority approval
The $43/share offer requires approval from Taro's minority shareholders; failure could derail the merger.
US Tariff and Policy Uncertainty
Potential US tariff changes and new administration policies could impact Sun Pharma's US generics and specialty business.
FDA Compliance at Halol Facility
Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.
Leqselvi Litigation Risk
If the patent litigation outcome is unfavorable, Leqselvi launch could be delayed until December 2026, impacting specialty growth.
Clinical Trial Delays Impacting R&D Pipeline
Delays in finalizing protocols and starting clinical trials have led to lower R&D spend and may push back pipeline milestones.
US generic sales pressure from competition
US generic sales declined due to additional competition on certain products, and recovery depends on resolving manufacturing compliance issues at several sites.
Proposed US Most Favored Nation pricing models
CMS proposed pricing models could impact US revenues; management declined to share mitigation strategies, citing commercial sensitivity.
Higher effective tax rate impacting PAT growth
Effective tax rate rose to ~25% from ~15% last year, dampening PAT growth relative to EBITDA growth; expected to remain in that range.
Milestone income may not recur
Management noted that milestone income of $55 million in Q3 may not recur in future quarters, potentially impacting revenue comparability.
FDA compliance issues at Mohali and Dadra plants
OAI status and 483 observations at Mohali and Dadra facilities could impact US generic launches and revenue.
Elevated R&D and launch costs pressuring margins
Higher R&D spend (8-10% of sales) and deuruxolitinib launch costs may compress EBITDA margins in FY25.
Pricing pressure from Stelara biosimilars
Stelara biosimilar entry next year could impact Ilumya pricing and market share in the US psoriasis market.
Currency depreciation in emerging markets
Nigeria forex loss and broader emerging market currency volatility could impact reported revenue and profitability.
US generic pricing pressure
US generics declined due to additional competition and pricing pressure, which may continue.
MFN/tariff policy uncertainty
Lack of clarity on MFN and tariff policies could impact US specialty pricing and access.
Leqselvi patent litigation risk
Leqselvi launch may be at risk due to ongoing patent litigation; potential damages if lost.
Tax rate increase
Effective tax rate rose to 19.8% in Q4 from 5.1% last year, expected to inch up further.